Ephedrine sulfate - Generic Drug Details

✉ Email this page to a colleague

What are the generic sources for ephedrine sulfate and what is the scope of freedom to operate?

Ephedrine sulfate is the generic ingredient in four branded drugs marketed by Exela Pharma, Endo Operations, Nexus, Amneal, Caplin, Dr Reddys, Eugia Pharma, Fresenius Kabi Usa, Gland Pharma Ltd, Hikma, Mankind Pharma, Renew Pharms, Sagent Pharms Inc, Sandoz, Xiromed, and Zydus Pharms, and is included in eighteen NDAs. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ephedrine sulfate has eleven patent family members in nine countries.

There are thirteen drug master file entries for ephedrine sulfate. Twenty-one suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for ephedrine sulfate

International Patents:	11
US Patents:	7
Tradenames:	4
Applicants:	16
NDAs:	18
Drug Master File Entries:	13
Finished Product Suppliers / Packagers:	21
Raw Ingredient (Bulk) Api Vendors:	21
Clinical Trials:	14
Patent Applications:	891
Drug Prices:	Drug price trends for ephedrine sulfate
What excipients (inactive ingredients) are in ephedrine sulfate?	ephedrine sulfate excipients list
DailyMed Link:	ephedrine sulfate at DailyMed

See drug prices for ephedrine sulfate

Recent Clinical Trials for ephedrine sulfate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Instituto Mexicano del Seguro Social	Phase 4
Fayoum University	Phase 1
Ain Shams University	N/A

See all ephedrine sulfate clinical trials

Generic filers with tentative approvals for EPHEDRINE SULFATE

Applicant	Application No.	Strength	Dosage Form
⤷ Sign Up	⤷ Sign Up	50MG/ML (50MG/ML)	SOLUTION;INTRAVENOUS

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for ephedrine sulfate

Drug Class	Norepinephrine Releasing Agent alpha-Adrenergic Agonist beta-Adrenergic Agonist
Mechanism of Action	Adrenergic alpha-Agonists Adrenergic beta-Agonists
Physiological Effect	Increased Norepinephrine Activity

Medical Subject Heading (MeSH) Categories for ephedrine sulfate

Adrenergic Agents
Central Nervous System Stimulants
Sympathomimetics
Vasoconstrictor Agents

Anatomical Therapeutic Chemical (ATC) Classes for ephedrine sulfate

Paragraph IV (Patent) Challenges for EPHEDRINE SULFATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
EPHEDRINE SULFATE	Injection	ephedrine sulfate	25 mg/5 mL and 50 mg/10 mL	213994	1	2023-03-17
EMERPHED	Injection	ephedrine sulfate	50 mg/10 mL	213407	1	2021-10-14

US Patents and Regulatory Information for ephedrine sulfate

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Nexus	EMERPHED	ephedrine sulfate	SOLUTION;INTRAVENOUS	213407-001	Apr 17, 2020		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Renew Pharms	EPHEDRINE SULFATE	ephedrine sulfate	SOLUTION;INTRAVENOUS	208609-001	Mar 1, 2017		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Exela Pharma	AKOVAZ	ephedrine sulfate	SOLUTION;INTRAVENOUS	208289-001	Apr 29, 2016	AP	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Nexus	EMERPHED	ephedrine sulfate	SOLUTION;INTRAVENOUS	213407-001	Apr 17, 2020		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Zydus Pharms	EPHEDRINE SULFATE	ephedrine sulfate	SOLUTION;INTRAVENOUS	217276-001	May 16, 2023		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Endo Operations	CORPHEDRA	ephedrine sulfate	SOLUTION;INTRAVENOUS	208943-001	Jan 27, 2017	AP	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Dr Reddys	EPHEDRINE SULFATE	ephedrine sulfate	SOLUTION;INTRAVENOUS	212649-001	Oct 3, 2020	AP	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for ephedrine sulfate

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Australia	2020276619	Compositions comprising ephedrine or an ephedrine salt and methods of making and using same	⤷ Sign Up
Japan	2023091072	エフェドリンまたはエフェドリン塩を含む組成物ならびにその組成物を作製する方法および使用する方法 (COMPOSITIONS COMPRISING EPHEDRINE OR EPHEDRINE SALT AND METHODS OF MAKING AND USING THOSE COMPOSITIONS)	⤷ Sign Up
Canada	3140043	COMPOSITIONS COMPRENANT DE L'EPHEDRINE OU UN SEL D'EPHEDRINE ET LEURS PROCEDES DE FABRICATION ET D'UTILISATION (COMPOSITIONS COMPRISING EPHEDRINE OR AN EPHEDRINE SALT AND METHODS OF MAKING AND USING SAME)	⤷ Sign Up
World Intellectual Property Organization (WIPO)	2020232424		⤷ Sign Up
World Intellectual Property Organization (WIPO)	2021150253		⤷ Sign Up
China	113825500	包含麻黄碱或麻黄碱盐的组合物及其制备和使用方法 (COMPOSITIONS COMPRISING EPHEDRINE OR AN EPHEDRINE SALT AND METHODS OF MAKING AND USING SAME)	⤷ Sign Up
Japan	2022532657	エフェドリンまたはエフェドリン塩を含む組成物ならびにその組成物を作製する方法および使用する方法	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

Supplementary Protection Certificates for ephedrine sulfate

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1110543	SPC/GB08/005	United Kingdom	⤷ Sign Up	SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022.
1110543	08C0004	France	⤷ Sign Up	PRODUCT NAME: DESLORATADINE; PSEUDOEPHEDRINE SULFATE; REGISTRATION NO/DATE: EU/1/07/399/001 20070730
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.